Synonyms: B4, B-lymphocyte antigen CD19
Coltuximab (Anti-CD19) is humanized IgG1 monoclonal antibody against CD19 with potential antineoplastic activity. MW : 144.7 KD.
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Name | Citation | CD38 | CD45 | CD39 | CD88 | CD73 | Others |
|---|---|---|---|---|---|---|---|
| RBN013209 | 0 | ||||||
| MK-0159 | 0 | ||||||
| CD38 inhibitor 1 (compound 78c) | 7 | ||||||
| AB680 | 1 | ||||||
| NQ301 | 1 | TXA2 receptor | |||||
| SodiuM Metatungstate | 3 | ||||||
| PMX-53 | 3 | ||||||
| LY-3475070 | 2 |
| Description |
Coltuximab (Anti-CD19) is humanized IgG1 monoclonal antibody against CD19 with potential antineoplastic activity. MW : 144.7 KD.
|
References |
|---|
| CAS No. | 1269764-99-9 |
|---|---|
| Molecular Weight | 144.7 |
| Isotype | Human IgG1 |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT03620058 | ACTIVE_NOT_RECRUITING | Chemotherapy Resistant Acute Lymphoblastic Leukemia; Refractory Acute Lymphoblastic Leukemia | University of Pennsylvania | 2018-09-27 | PHASE1 | |
| NCT07549698 | RECRUITING | Warm Autoimmune Hemolytic Anemia (WAIHA); ITP - Immune Thrombocytopenia; Warm Autoimmune Hemolytic Anemia; Immune Thrombocytopenic Purpura | CRISPR Therapeutics AG | 2026-06 | PHASE1; PHASE2 | |
| NCT06925542 | RECRUITING | SLE (Systemic Lupus); Lupus Erythematosus, Systemic; Lupus Nephritis; Systemic Sclerosis; Inflammatory Myopathy, Idiopathic; Myositis; Diffuse Cutaneous Systemic Sclerosis | CRISPR Therapeutics | 2025-03-10 | PHASE1 | |
| NCT07162571 | NOT_YET_RECRUITING | Acute Lymphobkastic Leukemia; B Cell Lymphoma | Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology | 2026-01-01 | PHASE1; PHASE2 | |
| NCT07162038 | RECRUITING | Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Mycophenolate | Hematologic Malignancies; Hematologic Neoplasms | National Cancer Institute (NCI) | 2025-11-14 | PHASE1 |
| NCT06377228 | WITHDRAWN | Drug: Chemotherapy Agents | Refractory Lupus Nephritis; Refractory Systemic Sclerosis | Takeda | 2025-06-13 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2025-10-14)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.